JPH09145710A - Method for detecting human hemoglobin in excretion - Google Patents

Method for detecting human hemoglobin in excretion

Info

Publication number
JPH09145710A
JPH09145710A JP29870295A JP29870295A JPH09145710A JP H09145710 A JPH09145710 A JP H09145710A JP 29870295 A JP29870295 A JP 29870295A JP 29870295 A JP29870295 A JP 29870295A JP H09145710 A JPH09145710 A JP H09145710A
Authority
JP
Japan
Prior art keywords
sample
antibody
human
human hemoglobin
feces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP29870295A
Other languages
Japanese (ja)
Other versions
JP3490560B2 (en
Inventor
Kenjiro Mori
健二郎 森
Masaru Sato
賢 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to JP29870295A priority Critical patent/JP3490560B2/en
Publication of JPH09145710A publication Critical patent/JPH09145710A/en
Application granted granted Critical
Publication of JP3490560B2 publication Critical patent/JP3490560B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To provide a method for detecting human Hb in excretion for eliminating the complex process with fear of taking a wrong specimen, simplifying operation, and suppressing the modification in human Hb when detecting human Hb(hemoglobin) in excretion by the immunity chromatography method. SOLUTION: After a sample 3 is arranged outside a region A1 on a water- absorbing base 4 having a region A1 where a first anti-human Hb antibody 1 is immobilized, a labeled second anti-human Hb antibody 2 is connected to the human Hb in the excretion of a sample according to the immunity chromatography method and the second anti-human Hb antibody 2 is developed into the region A1 by a development liquid 5, thus forming a complex of the human Hb in the sample, the first antibody, and the labeled second antibody, capturing the complex in the region A1, and hence detecting the human Hb in the sample. The sample excretion should be thinly applied.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、糞便中のヒトヘモ
グロビンを検出する方法に関する。
TECHNICAL FIELD The present invention relates to a method for detecting human hemoglobin in feces.

【0002】[0002]

【従来の技術】大腸癌などの下部消化器の疾患を検査す
る方法として、糞便中における、消化器官からの出血に
起因する潜血成分、特にヒトヘモグロビンの有無を調
べ、疾患を推定する方法が知られている。中でも、食品
摂取や薬剤投与の制限を必要としない抗ヒトヘモグロビ
ン抗体を用いた免疫学的検出方法が提案されている。こ
の様な糞便中のヒトヘモグロビンを検出する方法には、
例えば、動物血球に抗ヒトヘモグロビン抗体を感作した
ものと、糞便溶解液とを混合して生じる沈降現象を利用
して検出する逆受身血球凝集法、高分子ラテックス粒子
に抗ヒトヘモグロビン抗体を感作したものと、糞便溶解
液を混合して生じる凝集像を利用して検出するラテック
ス凝集法、酵素で標識した抗ヒトヘモグロビン抗体を利
用する酵素免疫法がある。
2. Description of the Related Art As a method for examining diseases of the lower digestive organs such as colorectal cancer, there is known a method of estimating the disease by examining the presence or absence of occult blood components caused by bleeding from digestive organs, particularly human hemoglobin, in feces. Has been. Above all, an immunological detection method using an anti-human hemoglobin antibody that does not require restriction of food intake or drug administration has been proposed. Such a method for detecting human hemoglobin in feces includes
For example, the reverse passive hemagglutination method, which detects by utilizing the precipitation phenomenon that occurs when animal blood cells are sensitized with anti-human hemoglobin antibody and fecal lysate, high molecular latex particles are sensitized with anti-human hemoglobin antibody. There are a latex agglutination method in which detection is performed by using an agglutination image produced by mixing the prepared one and a fecal lysate, and an enzyme immunoassay in which an enzyme-labeled anti-human hemoglobin antibody is used.

【0003】また、糞便中からヒトヘモグロビンをより
簡便に検出する方法として、免疫クロマト法が知られて
いる。免疫クロマト法は、吸水性基材上に、抗ヒトヘモ
グロビン抗体を固定化した固定相の領域を設け、該領域
においてヒトヘモグロビン及び着色粒子標識抗ヒトヘモ
グロビン抗体の複合体を結合させる事により、ヒトヘモ
グロビンを吸水性基材上にトラップし検出する方法であ
る。
An immunochromatography method is known as a method for more easily detecting human hemoglobin in feces. The immunochromatographic method comprises, on a water-absorbent substrate, providing a region of a stationary phase on which an anti-human hemoglobin antibody is immobilized, and binding a complex of human hemoglobin and a colored particle-labeled anti-human hemoglobin antibody in the region to bind to human. It is a method of detecting hemoglobin by trapping it on a water-absorbent substrate.

【0004】[0004]

【発明が解決しようとする課題】従来の免疫クロマト法
では、採取した糞便をいったん緩衝液等に溶解し、この
糞便溶解液を吸水性基材上に展開して測定を行ってい
た。具体的な検出手順としては、例えば、採便スティッ
クで少量の糞便を採取し、これを緩衝液の入ったノズル
付の検査用容器に入れて糞便溶解液とし、次にノズル先
端部を開口し、吸水性基材上に糞便溶解液を滴下して展
開させ検査するという手順が挙げられる。
In the conventional immunochromatographic method, the collected feces were once dissolved in a buffer solution or the like, and the fecal solution was spread on a water-absorbent substrate for measurement. As a specific detection procedure, for example, a small amount of stool is collected with a stool collection stick, and this is put into an inspection container with a nozzle containing a buffer solution to make a stool dissolution solution, and then the tip of the nozzle is opened. The procedure includes dropping a fecal solution on a water-absorbent substrate, developing the solution, and inspecting the solution.

【0005】従って、多数の試料を検査する場合には、
試料の数だけの検査用容器が必要であり、該容器に一つ
一つ糞便を溶解し、各々容器を開口して滴下する操作を
繰り返す必要があるため、検査作業者にとっては操作が
煩雑であり、また試料を取り違える恐れもあった。
Therefore, when inspecting a large number of samples,
Since it is necessary to have as many test containers as the number of samples, and it is necessary to dissolve the feces in each container one by one and repeat the operation of opening and dropping each container, the operation is complicated for the inspection operator. There was a risk that the samples would be mixed up.

【0006】また、ヒトヘモグロビンの立体構造は、糞
便溶解液中で腸内細菌や消化酵素等により、徐々に変性
することが知られている。しかし、実際上の便潜血検査
では、被験者自身が自宅等で糞便を採取し、これを緩衝
液入りの容器に入れて糞便溶解液とした状態で数日間放
置されることが多い。この様な場合、前記理由でヒトヘ
モグロビンが変性し、抗ヒトヘモグロビン抗体と結合し
にくくなるため、偽陰性化するおそれがあった。
It is also known that the three-dimensional structure of human hemoglobin is gradually denatured in the fecal lysate by intestinal bacteria, digestive enzymes and the like. However, in the actual fecal occult blood test, the subject himself / herself often collects feces at home or the like, puts the feces in a container containing a buffer solution, and leaves the feces dissolved solution for several days. In such a case, human hemoglobin is denatured for the above-mentioned reason, and it becomes difficult to bind to the anti-human hemoglobin antibody, which may result in false negative.

【0007】本発明の目的は、糞便中のヒトヘモグロビ
ンを免疫クロマト法に従って検出するに際し、検体を取
り違えるような煩雑さを改善し、簡便な操作で、かつ、
ヒトヘモグロビンの変性を抑制し得る、糞便中のヒトヘ
モグロビンの検出方法を提供することにある。
The object of the present invention is to improve the complexity of mistaking the sample when detecting human hemoglobin in the feces according to the immunochromatographic method, and with a simple operation, and
It is an object of the present invention to provide a method for detecting human hemoglobin in feces, which can suppress degeneration of human hemoglobin.

【0008】[0008]

【課題を解決するための手段】本発明は、次の特徴を有
するものである。 (1)第一の抗ヒトヘモグロビン抗体(以下、「第一の
抗体」という)が固定化された領域を有する吸水性基材
上の前記領域外に、試料の糞便を配置した後、免疫クロ
マト法に従い、試料中のヒトヘモグロビンに、標識化さ
れた第二の抗ヒトヘモグロビン抗体(以下、第二の抗ヒ
トヘモグロビン抗体を「第二の抗体」という)を結合さ
せ、これを展開液によって前記第一の抗体が固定化され
た領域まで展開させて、試料中のヒトヘモグロビン(以
下、ヒトヘモグロビンを「ヒトHb」という)と第一の
抗体と標識化された第二の抗体との複合体を形成させ第
一の領域に捕捉することによって、試料中のヒトHbを
検出することを特徴とする糞便中のヒトHbの検出方
法。
SUMMARY OF THE INVENTION The present invention has the following features. (1) After stool of a sample is placed outside the region on a water-absorbent substrate having a region to which a first anti-human hemoglobin antibody (hereinafter, referred to as “first antibody”) is immobilized, immunochromatography is performed. According to the method, a labeled second anti-human hemoglobin antibody (hereinafter, the second anti-human hemoglobin antibody is referred to as a "second antibody") is bound to human hemoglobin in the sample, A complex of human hemoglobin in a sample (hereinafter, human hemoglobin is referred to as "human Hb") and a second antibody labeled with the first antibody by expanding to a region where the first antibody is immobilized. A method for detecting human Hb in feces, which comprises detecting the human Hb in a sample by forming a matrix and capturing it in the first region.

【0009】(2)試料の糞便の配置が、試料の糞便を
厚さ3mm以下に塗布することによってなされるもので
ある上記(1)記載の糞便中のヒトHbの検出方法。
(2) The method for detecting human Hb in feces according to the above (1), wherein the feces of the sample are arranged by applying the feces of the sample to a thickness of 3 mm or less.

【0010】(3)試料の糞便の塗布が、試料の糞便を
試料塗布部材に塗布した後、これを吸水性基材に接触さ
せ転写させることによってなされるものである上記
(2)記載の糞便中のヒトHbの検出方法。
(3) Feces of the sample are applied by applying the feces of the sample to a sample application member and then contacting and transferring the sample with a water-absorbent substrate. Of detecting human Hb in blood.

【0011】(4)試料中のヒトHbと、標識化された
第二の抗体との結合が、展開液に標識化された第二の抗
体を含有させることによってなされるものである上記
(1)〜(3)記載の糞便中のヒトHbの検出方法。
(4) The binding of human Hb in the sample with the labeled second antibody is carried out by incorporating the labeled second antibody in the developing solution. ) To (3), the method for detecting human Hb in feces.

【0012】(5)試料中のヒトHbと、標識化された
第二の抗体との結合が、配置された試料の糞便と、第一
の抗体が固定化された領域との間に、標識化された第二
の抗体が固定化された領域を設けることによってなされ
るものである上記(1)〜(3)記載の糞便中のヒトH
bの検出方法。
(5) The binding between human Hb in the sample and the labeled second antibody is caused by the labeling between the feces of the arranged sample and the region where the first antibody is immobilized. Human H in feces according to the above (1) to (3), which is performed by providing a region in which the immobilized second antibody is immobilized.
b detection method.

【0013】(6)試料中のヒトHbと、標識化された
第二の抗体との結合が、配置された試料の糞便を挟ん
で、第一の抗体が固定化された領域とは反対側の領域
に、標識化された第二の抗体を固定化し、該標識化され
た第二の抗体に展開液を先に加え、これを配置された試
料の糞便へ展開させることによってなされるものである
上記(1)〜(3)記載の糞便中のヒトHbの検出方
法。
(6) The binding between human Hb in the sample and the labeled second antibody is on the opposite side of the region where the first antibody is immobilized, with the feces of the sample placed in between. In the area of, a labeled second antibody is immobilized, a developing solution is first added to the labeled second antibody, and this is developed in the feces of the sample in which it is placed. A certain method for detecting human Hb in feces according to the above (1) to (3).

【0014】[0014]

【作用】本発明の検出方法において、試料の糞便を配置
するとは、従来法のような試料の糞便を緩衝液に溶解す
ることを行わず、排泄された状態の組成で、または展開
させることを意図しない添加物が付与された組成で、試
料の糞便を配置することを意味する。ただし、乾燥など
による蒸発の有無は問わない。試料の糞便を配置するに
際しては、特に、後記説明の方法によって薄い厚みとな
るように塗布することが好ましい。このような試料の配
置によって、従来のように予め試料を緩衝液に溶解せず
とも、配置された試料に展開液を加えるだけで試料を吸
水性基材に展開させることができる。従って、試料を緩
衝液に溶解する作業工程が無くなり、検査作業が簡素化
される。また、これに伴い、その作業工程に固有の問題
点が解消される。特に、試料を緩衝液に溶解する従来の
方法では、腸内細菌や消化酵素等によるヒトHbの変性
が問題となっていたが、吸水性基材に試料を希釈しない
状態で配置することによって、糞便は徐々に乾燥し、腸
内細菌や消化酵素等によるヒトHbの変性は抑制され
る。従って、試料中のヒトHbについての保存性がより
改善される。
In the detection method of the present invention, arranging the feces of the sample means that the feces of the sample are not dissolved in a buffer solution as in the conventional method, but that the feces of the excreted composition are developed or developed. Means to place the feces of the sample in a composition provided with unintended additives. However, the presence or absence of evaporation due to drying or the like does not matter. When arranging the feces of the sample, it is particularly preferable to apply it so as to have a small thickness by the method described below. By arranging the sample as described above, the sample can be developed on the water-absorbent substrate simply by adding the developing solution to the arranged sample without previously dissolving the sample in the buffer solution. Therefore, the work process of dissolving the sample in the buffer is eliminated, and the inspection work is simplified. Further, along with this, the problems peculiar to the working process are solved. In particular, in the conventional method of dissolving a sample in a buffer solution, denaturation of human Hb due to intestinal bacteria, digestive enzymes, etc. has been a problem, but by arranging the sample in a water-absorbent substrate without diluting it, Feces are gradually dried, and the denaturation of human Hb by intestinal bacteria, digestive enzymes, etc. is suppressed. Therefore, the storage stability of human Hb in the sample is further improved.

【0015】[0015]

【発明の実施の形態】以下、本発明を図を用いて詳細に
説明する。図1は、本発明による検出方法に従って、糞
便中のヒトHbの検出を行なっている状態を模式的に示
す図である。同図に示すように、吸水性基材4上の領域
A1には、第一の抗体1が固定化されている。この吸水
性基材4上に、領域A1以外の領域A3に試料3(糞
便)を配置する。試料中にはヒトHbがあるものとす
る。また、同図の例は、標識化された第二の抗体2を展
開液5に含有させた場合の例である。この状態におい
て、領域A3に配置された試料3に対して免疫クロマト
法を適用する。即ち、試料に展開液を加え、該試料中の
ヒトHbに、標識化された第二の抗体を結合させ、これ
を同図中の矢印6の方向で示すように、展開液によって
領域A1まで展開させる。これによって、領域A1にお
いて、試料中のヒトHbと第一の抗体と標識化された第
二の抗体との複合体が形成され、試料中のヒトHbは第
一の抗体によって領域A1に捕捉される。捕捉されたヒ
トHbは、第二の抗体の標識によって検出することがで
きる。
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the drawings. FIG. 1 is a diagram schematically showing a state in which human Hb in feces is being detected according to the detection method of the present invention. As shown in the figure, the first antibody 1 is immobilized in the region A1 on the water-absorbent substrate 4. On this water absorbent substrate 4, the sample 3 (feces) is placed in the area A3 other than the area A1. Human Hb is assumed to be present in the sample. In addition, the example of the same figure is an example in which the labeled second antibody 2 is contained in the developing solution 5. In this state, the immunochromatography method is applied to the sample 3 arranged in the area A3. That is, a developing solution is added to the sample, and the labeled second antibody is bound to human Hb in the sample, and as shown by the direction of arrow 6 in the figure, the developing solution reaches the region A1. Deploy. As a result, in the area A1, a complex of human Hb in the sample, the first antibody and the labeled second antibody is formed, and the human Hb in the sample is captured by the first antibody in the area A1. It The captured human Hb can be detected by the label of the second antibody.

【0016】吸水性基材は、当該試料に対して免疫クロ
マト法が適用可能な材料であればよい。即ち、展開液を
よく吸収し、試料内のヒトHb、標識化された第二の抗
体を展開できるものであれば特に限定されない。また吸
水性基材は、糞便中のヒトHbが、標識化された第二の
抗体や、固定化された第一の抗体と十分な反応を行うた
めの時間を確保するために、適度な吸水性を有するもの
が好ましい。該吸水性が低い場合は、展開が遅く迅速な
測定を行うことができない。逆に吸水性が高すぎる場合
は、展開が早くヒトHbが第二および第一の抗体と十分
な反応を行うための時間が不足するので、十分な標識の
効果が得られず、判定が困難になる。
The water-absorbent substrate may be any material to which the immunochromatographic method can be applied to the sample. That is, it is not particularly limited as long as it can well absorb the developing solution and develop the human Hb in the sample and the labeled second antibody. In addition, the water-absorbent substrate has an appropriate water-absorbing property in order to ensure sufficient time for human Hb in feces to sufficiently react with the labeled second antibody and the immobilized first antibody. Those having properties are preferable. When the water absorption is low, the development is slow and rapid measurement cannot be performed. On the other hand, if the water absorption is too high, the development is rapid and the time for human Hb to react sufficiently with the second and first antibodies is insufficient, so sufficient labeling effect cannot be obtained, and determination is difficult. become.

【0017】吸水性基材の好ましい材料としては、例え
ばレーヨン、ポリエステル等の不織布、濾紙、ガラス繊
維布、ガラスフィルター、ニトロセルロースフィルタ
ー、多孔質材料等が挙げられる。また、吸水性基材の吸
水性を調整するために、当該吸水性基材に親水性重合
体、タンパク質、乳化剤を、被覆または含浸させてもよ
い。また、吸水性基材は、単一材料からなるものでも、
複数種の材料からなるものでもよい。吸水性基材が複数
の材料からなる場合は、異なる材料が面方向に接合され
た態様や、異なる材料が積層された態様が挙げられる。
吸水性基材の形状は、展開液によって試料を展開できる
形状であれば特に限定されるものではない。例えば、矩
形のシート状やロッド状などが好ましい。
Preferred materials for the water-absorbent substrate include, for example, non-woven fabric such as rayon and polyester, filter paper, glass fiber cloth, glass filter, nitrocellulose filter, porous material and the like. Further, in order to adjust the water absorption property of the water absorbent substrate, the water absorbent substrate may be coated or impregnated with a hydrophilic polymer, protein or emulsifier. Further, the water-absorbent substrate, even if made of a single material,
It may be made of plural kinds of materials. When the water-absorbent substrate is composed of a plurality of materials, examples include a mode in which different materials are joined in the surface direction and a mode in which different materials are laminated.
The shape of the water-absorbent substrate is not particularly limited as long as the sample can be spread with the developing solution. For example, a rectangular sheet shape or a rod shape is preferable.

【0018】第一の抗体としては、ヒトHbと特異的に
結合し得る抗体であれば特に限定されない。例えば、抗
ヒトHbウサギポリクロナール抗体、抗ヒトHbヤギポ
リクロナール抗体、抗ヒトHbヒツジポリクロナール抗
体、抗ヒトHbモノクロナール抗体などが挙げられる。
The first antibody is not particularly limited as long as it is an antibody that can specifically bind to human Hb. Examples thereof include anti-human Hb rabbit polyclonal antibody, anti-human Hb goat polyclonal antibody, anti-human Hb sheep polyclonal antibody, anti-human Hb monoclonal antibody and the like.

【0019】吸水性基材上に第一の抗体を固定化する方
法は、特に限定されるものではないが、公知の吸着法や
共有結合法が好ましい方法である。共有結合法による場
合、吸水性基材が共有結合法のための官能基を有しない
ときは、例えば、適宜の官能基を有する重合体を基材に
付着させればよい。また、第一の抗体と親水性重合体と
の混合液を吸水性基材に塗布した後、前記親水性重合体
を凝固させる凝固浴剤に浸漬することによって、第一の
抗体を固定化することができる。上記親水性重合体とし
ては、ヒドロキシプロピルメチルセルロース、ポリビニ
ルアルコール、ヒドロキシエチルセルロース等が、凝固
浴としてはアセトン、メタノール、エタノール等が用い
られる。
The method for immobilizing the first antibody on the water-absorbent substrate is not particularly limited, but a known adsorption method or covalent bond method is a preferable method. In the case of the covalent bonding method, when the water-absorbent substrate does not have a functional group for the covalent bonding method, for example, a polymer having an appropriate functional group may be attached to the substrate. Further, the first antibody is immobilized by applying a mixed solution of the first antibody and the hydrophilic polymer onto a water-absorbent substrate, and then immersing the mixture in a coagulation bath agent that coagulates the hydrophilic polymer. be able to. Hydroxypropylmethyl cellulose, polyvinyl alcohol, hydroxyethyl cellulose and the like are used as the hydrophilic polymer, and acetone, methanol, ethanol and the like are used as the coagulation bath.

【0020】試料を配置するに際しては、上記作用の説
明で述べたように、従来法のような試料を緩衝液に溶解
することは行わず、排泄された状態の組成で配置する。
排泄された状態の組成は、排泄から配置までの蒸発によ
る水分等の含有量の変化を問題としない。また、場合に
よっては、試料を軟化させてより容易に配置する目的や
保存の目的など試料を展開させる以外の目的で、また、
試料を展開させない範囲内で必要な添加物を必要量だけ
試料に付与してもよい。例えば、試料を軟化させ吸水性
基材への塗布を容易にするための添加物として水などの
希釈液が挙げられるが、従来行われていた免疫クロマト
法が成立するような展開が試料に起こり得ない量の添加
とする。
When the sample is placed, as described in the explanation of the above-mentioned action, the sample is not dissolved in the buffer solution as in the conventional method, but is placed in the excreted composition.
The composition in the excreted state does not cause a change in the content of water and the like due to evaporation from excretion to placement. In addition, in some cases, for the purpose other than developing the sample, such as the purpose of softening the sample for easier placement and the purpose of storage,
The necessary amount of additive may be added to the sample within a range in which the sample is not developed. For example, a diluent such as water may be used as an additive for softening the sample and facilitating its application to the water-absorbent substrate. Add an amount that cannot be obtained.

【0021】配置される試料の量は、0.05mg〜1
0mg程度が好ましい。また、配置される試料の厚さは
3mm以下が好ましい。厚すぎる場合、後述する糞便の
乾燥に時間がかかり、この間に糞便中のヒトHbが変性
する恐れがある。
The amount of the sample placed is 0.05 mg to 1
About 0 mg is preferable. Moreover, the thickness of the sample to be placed is preferably 3 mm or less. If it is too thick, it takes time to dry the feces described below, and human Hb in the feces may be denatured during this time.

【0022】試料を吸水性基材上に配置する方法として
は、試料の厚みが薄い方が好ましいという点から、塗布
が好ましい方法である。塗布の方法としては、特に限定
されないが、吸水性基材とは別に試料塗布部材を用意
し、これに試料を配置し、これを吸水性基材上の試料配
置位置に接触させて転写する方法が好ましい方法として
挙げられる。試料塗布部材としては、濾紙、不織布、ガ
ラスフィルター等が挙げられる。
As a method for arranging the sample on the water-absorbent substrate, coating is a preferable method because it is preferable that the sample is thin. The coating method is not particularly limited, but a method for preparing a sample coating member separately from the water-absorbent substrate, arranging the sample on it, and transferring it by bringing it into contact with the sample-arranged position on the water-absorbent substrate. Is a preferred method. Examples of the sample application member include filter paper, non-woven fabric, glass filter and the like.

【0023】また、先端付近に凹部や溝部等を有するス
ティックで試料を採取し、該スティックの凹部や溝部に
収容された試料を、吸水性基材の試料配置位置に接触さ
せて転写する方法が挙げられる。この様なスティックを
用いた場合、一定体積の凹部、溝部に定量的に試料をと
ることができるので測定の精度が向上する。
Further, there is a method in which a sample is taken with a stick having a recess or groove near the tip, and the sample contained in the recess or groove of the stick is brought into contact with the sample placement position of the water-absorbent substrate to transfer the sample. Can be mentioned. When such a stick is used, the sample can be quantitatively taken in the concave portion and the groove portion having a constant volume, so that the measurement accuracy is improved.

【0024】試料の配置方法によらず、吸水性基材上
に、吸水性基材と同様の展開性を有する試料配置用部材
を設置し、これに試料を配置してもよい。試料配置用部
材としては、例えば、濾紙、不織布、ガラスフィルター
などが好ましいものとして挙げられる。また、吸水性基
材上に、PETなどのポリマーフィルムによる非吸水性
層を積層し、この非吸水性層に部分的に貫通孔を設けて
下層の吸水性基材の表面を露出させることによって、そ
の貫通孔を試料の定量的な配置に利用してもよい。
Regardless of the sample arranging method, a sample arranging member having the same developability as that of the water absorbing base material may be installed on the water absorbing base material, and the sample may be arranged thereon. Preferable examples of the sample placement member include filter paper, non-woven fabric, and glass filter. In addition, by laminating a non-water-absorbing layer made of a polymer film such as PET on a water-absorbing substrate and partially forming through holes in the non-water-absorbing layer to expose the surface of the lower water-absorbing substrate. The through holes may be used for quantitatively arranging the sample.

【0025】試料の糞便は、吸水性基材上に配置された
直後の未乾燥のものでも、保存等によって長時間が経過
した後の乾燥したものでも、免疫クロマト法の適用が可
能である。配置された直後の試料であれば、試料中のヒ
トHbは、ほとんど変性していないので、正確な検出が
行える。また、吸水性基材上に配置された後、一定時間
経過した試料は、従来のような緩衝液に溶解されたもの
とは異なり、糞便中での消化酵素や腸内細菌によるヒト
Hbを変性する反応が乾燥によって抑制されるので、陽
性検体が偽陰性化することを防ぐことが出来る。配置し
た試料の乾燥は、通気性のよい状態で放置しておいても
よいが、乾燥剤を入れた密閉袋、容器に入れた方がより
速く乾燥し好ましい。
The immunochromatographic method can be applied to the stool of the sample, whether it is undried immediately after being placed on the water-absorbent substrate or dried after a long time has passed due to storage or the like. In the case of the sample immediately after being placed, since human Hb in the sample is hardly denatured, accurate detection can be performed. In addition, the sample that has been placed on the water-absorbent substrate for a certain period of time is different from the one dissolved in a conventional buffer solution, unlike the sample dissolved in a conventional buffer solution, which denatures human Hb due to digestive enzymes and intestinal bacteria. Since the reaction that occurs is suppressed by drying, it is possible to prevent a positive sample from becoming a false negative. The placed sample may be dried in a well-ventilated state, but it is preferable to put it in a closed bag or a container containing a desiccant because the sample dries faster.

【0026】以上の特徴を有する方法によって吸水性基
材上に試料を配置し、下記の特徴を有する方法によって
該試料に対して免疫クロマト法を適用する。即ち、吸水
性基材上に配置された試料に展開液を加え、該試料中の
ヒトHbに標識化された第二の抗体を結合させ、これを
第一の抗体が固定化された領域まで展開させ、その領域
にヒトHbをトラップして検出する。
The sample is placed on the water-absorbent substrate by the method having the above characteristics, and the immunochromatography method is applied to the sample by the method having the following characteristics. That is, a developing solution is added to the sample placed on the water-absorbent substrate, the labeled second antibody is bound to human Hb in the sample, and this is transferred to the region where the first antibody is immobilized. It is developed and human Hb is trapped and detected in that region.

【0027】展開液は、従来より使用されている緩衝液
など、免疫クロマト法を行うことが出来るものであれば
特に制限されない。緩衝液としては、リン酸緩衝液、グ
リシン緩衝液、ほう酸緩衝液などが公知である。また、
ヒトHbと抗体との反応性をよくするために、塩化ナト
リウムを生理食塩水濃度で加えてもよい。緩衝液の成
分、pHは、後述の標識化された第二の抗体が自然凝集
しないものが好ましい。標識化された第二の抗体が自然
凝集した場合、着色粒子などの標識化のための物質が吸
水性基材中で目詰まりを起こし、非特異的発色が生じる
からである。pHは通常、中性付近の5〜9が用いられ
る。
The developing solution is not particularly limited as long as it can carry out the immunochromatographic method such as a buffer solution which has been conventionally used. As the buffer solution, a phosphate buffer solution, a glycine buffer solution, a borate buffer solution and the like are known. Also,
Sodium chloride may be added at a physiological saline concentration in order to improve the reactivity between human Hb and the antibody. The components and pH of the buffer solution are preferably such that the labeled second antibody described below does not spontaneously aggregate. This is because when the labeled second antibody spontaneously aggregates, a labeling substance such as colored particles causes clogging in the water-absorbent substrate, resulting in non-specific color development. The pH is usually around 5 to 9 which is near neutral.

【0028】試料に対して展開液を加える方法は、試料
に対して展開液を直接的に滴下・添加する方法でも、吸
水性基材の他の領域(吸水部)に滴下・添加し、試料に
到達させて加える方法でもよい。また、展開液を一定量
が液滴となって取り出せるノズル付容器などに入れてお
き、所定滴数を吸水性基材・試料へ添加する方法、逆
に、吸水性基材の吸水部を、一検体分の展開液が入れら
れたウエルへ浸漬する方法などが、操作手順を簡便にす
る方法である。
As for the method of adding the developing solution to the sample, the method of directly dropping and adding the developing solution to the sample can also be used by dropping and adding the developing solution to another region (water absorbing part) of the water-absorbent substrate. It may be a method of reaching and adding. Further, a method in which the developing solution is put in a container with a nozzle or the like that can take out a fixed amount of liquid droplets, and a predetermined number of drops is added to the water-absorbing base material / sample, conversely, A method of simplifying the operation procedure is, for example, a method of immersing the sample in a well containing a developing solution.

【0029】試料中のヒトHbと、標識化された第二の
抗体との結合は、試料中のヒトHbが第一の抗体の領域
に到達する前であれば、いつ行なってもよいが、大きく
は、次の方法による結合が挙げられる。 (a)図1に示すように、展開液に、標識化された第二
の抗体を含有させておく方法。この展開液を、試料、第
一の抗体の順番で通過するように吸水性基材に添加する
ことによって、試料中のヒトHbと、標識化された第二
の抗体との結合が先になされる。 (b)吸水性基材上に、標識化された第二の抗体を固定
化しておく方法。その固定化の位置は、試料が配置され
る位置の前後いずれであってもよいが、各々の場合に、
展開液が次の順番で通過するように、該展開液を吸水性
基材に添加することが重要である。即ち、図2(a)に
示すように、標識化された第二の抗体2、試料3、第一
の抗体1の順番。または、図2(b)に示すように、試
料3、標識化された第二の抗体2、第一の抗体1の順
番。
The binding of human Hb in the sample to the labeled second antibody may be performed at any time before the human Hb in the sample reaches the region of the first antibody. In general, the following methods can be used for binding. (A) A method in which a developing solution contains a labeled second antibody as shown in FIG. By adding this developing solution to the water-absorbent substrate so that the sample and the first antibody pass through in this order, the binding of the human Hb in the sample and the labeled second antibody is performed first. It (B) A method of immobilizing a labeled second antibody on a water-absorbent substrate. The position of the immobilization may be before or after the position where the sample is arranged, but in each case,
It is important to add the developing solution to the water-absorbent substrate so that the developing solution passes through in the following order. That is, as shown in FIG. 2A, the labeled second antibody 2, the sample 3, and the first antibody 1 are in this order. Alternatively, as shown in FIG. 2B, the sample 3, the labeled second antibody 2, and the first antibody 1 are arranged in this order.

【0030】第二の抗体としては、ヒトHbと特異的に
結合する抗体であれば特に限定されない。例えば抗ヒト
Hbウサギポリクロナール抗体、抗ヒトHbヤギポリク
ロナール抗体、抗ヒトHbヒツジポリクロナール抗体、
抗ヒトHbモノクロナール抗体などが挙げられる。
The second antibody is not particularly limited as long as it is an antibody that specifically binds to human Hb. For example, anti-human Hb rabbit polyclonal antibody, anti-human Hb goat polyclonal antibody, anti-human Hb sheep polyclonal antibody,
Anti-human Hb monoclonal antibody etc. are mentioned.

【0031】標識としては、第二の抗体に結合し得るも
のであればよいが着色粒子が特に好ましいものとして挙
げられる。着色粒子としては金、銀、銅等のコロイド状
金属粒子、着色化高分子ラテックス粒子、顔料粒子等が
用いられるが、特に金コロイド粒子、着色化高分子ラテ
ックス粒子が好ましい。着色粒子の粒子径は、用いられ
る吸水性基材に目詰まりしない範囲とすることが好まし
く、0.01μm〜3μm程度がよい。
Any label may be used as long as it can bind to the second antibody, and colored particles are particularly preferable. As the colored particles, colloidal metal particles of gold, silver, copper or the like, colored polymer latex particles, pigment particles and the like are used, but gold colloid particles and colored polymer latex particles are particularly preferable. The particle size of the colored particles is preferably in a range that does not cause clogging of the water-absorbent substrate used, and is preferably about 0.01 μm to 3 μm.

【0032】第二の抗体に着色粒子を結合する方法は、
従来より知られている物理吸着法や化学結合法が用いら
れる。特に、官能基を粒子表面に有する着色粒子を用
い、これを共有結合法によって第二の抗体に結合する方
法が好ましい。例えば、アミノ基やカルボキシル基を有
する着色粒子に、結合試薬として水溶性カルボジイミド
を用いて抗体を共有結合する方法が例示される。
The method of binding the colored particles to the second antibody is as follows:
The conventionally known physical adsorption method or chemical bonding method is used. In particular, a method of using colored particles having a functional group on the particle surface and binding the colored particles to the second antibody by a covalent bond method is preferable. For example, a method of covalently binding an antibody to a colored particle having an amino group or a carboxyl group by using a water-soluble carbodiimide as a binding reagent is exemplified.

【0033】上記(b)のように、吸水性基材上に標識
化された第二の抗体を固定化しておく方法では、標識化
された第二の抗体が、展開液と接触して、吸水性基材か
ら脱離し得るように吸水性基材に固定化することが重要
である。例えば、標識化された第二の抗体を吸水性基材
に塗布した後、適当な条件にて乾燥させ固定化する方法
が挙げられる。具体的には、水溶性重合体あるいはサッ
カロースの溶液に、標識化された第二の抗体を分散さ
せ、この液を吸水性基材に塗布した後、乾燥させる方法
が挙げられる。この方法で第二の抗体を固定化すること
によって、固定化された部分に展開液が接触したとき
に、水溶性重合体またはサッカロースが容易に水溶性化
し、標識化された第二の抗体が速やかに基材から脱離す
る。また、この方法では、乾燥に際して第二の抗体の凝
集や変成が生じ難く、更に、乾燥後に第二の抗体が吸水
性基材から脱離し難い。また、標識化された第二の抗体
を吸水性基材の所定の領域に好適に含有させ得るよう、
水溶性重合体あるいはサッカロースの濃度を調整し、溶
液を適当な粘度とすることが好ましい。また、標識化さ
れた第二の抗体を他の吸水性基材上に固定化し、これを
適当な形状に加工して、メインの吸水性基材に貼付して
もよい。
In the method of immobilizing the labeled second antibody on the water-absorbent substrate as described in (b) above, the labeled second antibody is brought into contact with the developing solution, It is important to immobilize on the water absorbent substrate so that it can be detached from the water absorbent substrate. For example, a method of applying a labeled second antibody to a water-absorbent substrate and then drying and immobilizing it under appropriate conditions can be mentioned. Specifically, a method in which a labeled second antibody is dispersed in a solution of a water-soluble polymer or sucrose, the solution is applied to a water-absorbent substrate, and then dried is exemplified. By immobilizing the second antibody by this method, when the developing solution comes into contact with the immobilized part, the water-soluble polymer or saccharose easily becomes water-soluble, and the labeled second antibody becomes Detach from the substrate immediately. In addition, in this method, aggregation and modification of the second antibody are unlikely to occur during drying, and further, the second antibody is less likely to be released from the water-absorbent substrate after drying. Further, in order to allow the labeled second antibody to be suitably contained in a predetermined region of the water-absorbent substrate,
It is preferable to adjust the concentration of the water-soluble polymer or saccharose so that the solution has an appropriate viscosity. Alternatively, the labeled second antibody may be immobilized on another water-absorbent substrate, processed into an appropriate shape, and attached to the main water-absorbent substrate.

【0034】上記水溶性重合体としては、例えば、ポリ
ビニルピロリドン、ポリビニルアルコール、ポリエチレ
ングリコール、セルロースエーテル(例えば、メチルセ
ルロース、エチルセルロース、ベンジルセルロース、ト
リチルセルロース、シアンエチルセルロース、カルボキ
シルメチルセルロース、カルボキシルエチルセルロー
ス、オキシエチルセルロース)、ゼラチン等が好ましく
用いられる。
Examples of the water-soluble polymer include polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, cellulose ethers (eg, methyl cellulose, ethyl cellulose, benzyl cellulose, trityl cellulose, cyanethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, oxyethyl cellulose), Gelatin or the like is preferably used.

【0035】次に、本発明による検出方法の手順につい
て述べる。試料の糞便には、ヒトHbが含まれていたと
する。前述した方法によって、試料の糞便を、吸水性基
材上に直接または試料配置用部材を介して配置する。試
料の配置後、直ちに検出を行わない場合は、前述した乾
燥方法で試料を乾燥させ、試料中のヒトHbの変性を抑
制する。
Next, the procedure of the detection method according to the present invention will be described. It is assumed that the sample feces contained human Hb. By the method described above, the feces of the sample are placed on the water-absorbent substrate directly or via the sample placement member. When the detection is not performed immediately after placing the sample, the sample is dried by the above-described drying method to suppress the denaturation of human Hb in the sample.

【0036】展開液を加えることにより、配置された試
料が溶解し試料中のヒトHbが抽出される。このヒトH
bと標識化された第二の抗体とが上記説明の方法によっ
て結合し、複合体を形成する。展開液が吸水性基材中を
流れることによって、前記複合体も移動し、第一の抗体
が固定化された領域に到達する。この領域において前記
複合体は、固定化された第一の抗体と結合することによ
って捕捉される。その結果、試料中にヒトHbが一定量
以上存在するとき、第一の抗体が固定化された領域に標
識が固定されることになり、この標識を肉眼観察又は光
学的に測定することでヒトHbの存在又は量を知ること
が出来る。上記において、試料中の全てのヒトHbを第
二の抗体と結合させて複合体を形成することは難しく、
また該複合体のすべてを第一の抗体と結合させることも
難しいことから、試料中のヒトHbの存在が一定量未満
の場合には、前記領域に固定される標識化された第二の
抗体の数はより少なくなり、肉眼観察又は光学的に測定
することが困難となる。
By adding the developing solution, the arranged sample is dissolved and human Hb in the sample is extracted. This human H
b and the labeled second antibody are bound by the method described above to form a complex. By flowing the developing solution through the water-absorbent substrate, the complex also moves and reaches the region where the first antibody is immobilized. In this region the complex is captured by binding to the immobilized first antibody. As a result, when human Hb is present in a certain amount or more in the sample, the label is immobilized on the region where the first antibody is immobilized, and the human is detected by visual observation or optical measurement of this label. The existence or amount of Hb can be known. In the above, it is difficult to combine all human Hb in the sample with the second antibody to form a complex,
Further, since it is difficult to bind all of the complex to the first antibody, when the amount of human Hb in the sample is less than a certain amount, the labeled second antibody immobilized in the region is fixed. Are smaller, and are difficult to observe visually or to measure optically.

【0037】[0037]

【実施例】以下、実施例を挙げて本発明を具体的に示
す。 実施例1 本実施例は、標識化のための物質として着色粒子を用
い、これによって標識化された第二の抗体を展開液に含
有させておき、この展開液を試料に加えた場合の例であ
る。
EXAMPLES The present invention will be specifically described below with reference to examples. Example 1 In this example, colored particles are used as a substance for labeling, a second antibody labeled by the colored particles is contained in a developing solution, and the developing solution is added to a sample. Is.

【0038】(1)標識化された第二の抗体の作製 着色粒子として青色カルボキシル化ポリスチレンラテッ
クス(平均粒子径0.22μm)を用い、これを0.0
1Mほう酸緩衝液(pH7.5)に固形分濃度1%とな
るように分散させた。この分散液10mlに1−エチル
−3−(3−ジメチルアミノプロピル)カルボジイミド
塩酸塩水溶液(5mg/ml)0.2mlを加え、10
℃にて10分間攪拌した後、第二の抗体として抗ヒトH
bウサギポリクロナール抗体(10mg/ml) 2ml
を加え、10℃にて24時間攪拌した。これを前記と同
じ緩衝液にて遠心洗浄し固形分濃度1%となるよう再分
散させ、青色ラテックス粒子によって標識化された第二
の抗体を得た。
(1) Preparation of labeled second antibody Blue carboxylated polystyrene latex (average particle diameter 0.22 μm) was used as the colored particles, and this was used as 0.0
It was dispersed in a 1 M borate buffer (pH 7.5) so that the solid content concentration was 1%. To 10 ml of this dispersion was added 0.2 ml of an aqueous solution of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (5 mg / ml), and 10
After stirring for 10 minutes at ℃, anti-human H as the second antibody
b Rabbit polyclonal antibody (10mg / ml) 2ml
Was added and stirred at 10 ° C. for 24 hours. This was centrifugally washed with the same buffer as above and redispersed to a solid concentration of 1% to obtain a second antibody labeled with blue latex particles.

【0039】(2)吸水性基材に対する第一の抗体の固
定化 第一の抗体として抗ヒトHbウサギポリクロナール抗体
を用い、0.1Mリン酸緩衝液(NaCl;0.9%含
有、pH7.4)にて希釈し、1mg/mlの溶液に調
整した。吸水性基材として、ニトロセルロース膜(組織
の孔径1μm、外形5mm×100mm、厚み0.15
mm)を用い、その一端から20mmの部位に、第一の
抗体を含む上記溶液を1μl塗布し、室温で一夜乾燥し
た。次にこれを1%ウシ血清アルブミン水溶液に1時間
浸漬した後、室温で一夜乾燥し、第一の抗体が固定化さ
れた領域を有する吸水性基材を得た。
(2) Immobilization of the first antibody on the water-absorbent substrate Using an anti-human Hb rabbit polyclonal antibody as the first antibody, 0.1M phosphate buffer (NaCl; 0.9% content, pH 7. It diluted with 4) and adjusted to the solution of 1 mg / ml. As a water-absorbent substrate, a nitrocellulose membrane (tissue pore diameter 1 μm, outer shape 5 mm × 100 mm, thickness 0.15
mm), and 1 μl of the above-mentioned solution containing the first antibody was applied to a site 20 mm from one end thereof and dried overnight at room temperature. Next, this was immersed in a 1% bovine serum albumin aqueous solution for 1 hour and then dried overnight at room temperature to obtain a water-absorbent substrate having a region where the first antibody was immobilized.

【0040】(3)吸水性基材に対する付帯部品の付与 PETフィルム(厚さ25μm、5×100mm)の一
端から10mmの部位にφ2mmの貫通孔を開け、この
孔の部位と、上記吸水性基材上の第一の抗体の位置との
間隔が50mmになるようにPETフィルムと吸水性基
材とを貼合わせて、ニトロセルロース/PETフィルム
を形成した。次に、吸水性基材上の、第一の抗体の位置
とは逆の一端に吸水部として、レーヨン不織布(厚さ
2.4mm、5×5mm)を貼付した。
(3) Provision of incidental parts to the water-absorbent substrate: A PET film (thickness: 25 μm, 5 × 100 mm) was provided with a through hole of φ2 mm at a site 10 mm from one end, and the site of this hole and the water-absorbent group The PET film and the water-absorbent substrate were bonded together so that the distance from the position of the first antibody on the material was 50 mm to form a nitrocellulose / PET film. Next, a rayon nonwoven fabric (thickness: 2.4 mm, 5 × 5 mm) was attached to one end of the water-absorbent substrate opposite to the position of the first antibody as a water-absorbing portion.

【0041】(4)試料の作製 試料は、糞便1g中のヒトHbの含有量が、1μg、5
μg、15μg、30μg、60μg、120μg、1
000μgの7種類とした。これら7種類の含有量の試
料は、健常者の糞便に対してヒトHbを新たに適当量だ
け添加し混合することによって作製した。またその作製
の際には、糞便1g中のヒトHbの含有量を、EIAキ
ット(わかもと製薬、チェックメイトヘモ等)を用いて
定量し、確認して調製した。また、試料中のヒトHbが
失活しないように、下記ヒトHbの検出実験開始までの
間、試料を冷凍保存した。
(4) Preparation of sample The sample contained 1 μg of human Hb in 1 g of feces and 5
μg, 15 μg, 30 μg, 60 μg, 120 μg, 1
Seven kinds of 000 μg were used. Samples with these 7 kinds of contents were prepared by newly adding an appropriate amount of human Hb to the stool of a healthy person and mixing them. Further, in the preparation, the content of human Hb in 1 g of feces was quantified using an EIA kit (Wakamoto Pharmaceutical Co., Checkmate Haemo, etc.), and confirmed and prepared. In addition, the sample was frozen and stored until the start of the following human Hb detection experiment so that the human Hb in the sample is not inactivated.

【0042】(5)試料の配置 上記(3)で作製したニトロセルロース/PETフィル
ムの貫通孔内に、上記(4)で作製した試料であるヒト
Hbを含有する糞便(7種類)を各々塗布し、穴からは
み出した過剰便はヘラ状の治具でぬぐいとった。(約
0.08mgの便が穴に入る)
(5) Arrangement of Samples Feces (7 types) containing human Hb, which is the sample prepared in (4) above, were applied into the through holes of the nitrocellulose / PET film prepared in (3) above. However, the excess stool that had protruded from the hole was wiped off with a spatula-shaped jig. (Approximately 0.08 mg of stool enters the hole)

【0043】(6)試料中のヒトHbの検出 上記(1)で作製した標識化された第二の抗体を0.1
Mリン酸緩衝液(NaCl;0.9%、アジ化ナトリウ
ム;0.1%含有、pH7.4)にて希釈し、0.01
%の展開液(分散液)を調整した。この展開液100μ
lを、試料を塗布した直後に吸水性基材に対して吸水部
から添加し、試料を第一の抗体の領域まで到達させて、
10分後の固定部の発色を肉眼で観察し、ヒトHbの検
出を行った。また、同じ試料を同様の方法で配置した吸
水性基材を別途作製し、シリカゲル(タブレット状、1
g)入りのチャック袋(6×12cm)に入れて密封
し、37℃で3日間、および6日間保存し水分を蒸発さ
せた後、前記と同様に各々に分散液を添加してヒトHb
の検出を行った。
(6) Detection of human Hb in a sample The labeled second antibody prepared in (1) above was used in 0.1
Dilute with M phosphate buffer (NaCl; 0.9%, sodium azide; 0.1% content, pH 7.4) and add 0.01
% Developing solution (dispersion) was prepared. This developing solution 100μ
Immediately after applying the sample, 1 is added to the water-absorbent substrate from the water-absorbing part to allow the sample to reach the region of the first antibody,
Coloring of the fixed part after 10 minutes was visually observed to detect human Hb. In addition, a water-absorbent substrate in which the same sample is arranged in the same manner is separately prepared, and silica gel (tablet-like, 1-
g) Put in a zipper bag (6 × 12 cm) and sealed, store at 37 ° C. for 3 days and 6 days to evaporate water, and then add the dispersion liquid to each in the same manner as above to add human Hb.
Was detected.

【0044】下記表1は、上記7種類のヒトHb含有量
の試料について、試料を塗布した直後の検出結果、37
℃で3日間および6日間保存し水分を蒸発させた後の検
出結果を示すものである。下記表1から明らかなよう
に、検出結果に経時的な差異がなく、試料中のヒトHb
の経時的な変性が抑制されていることがわかる。
The following Table 1 shows the detection results of the above 7 kinds of human Hb content samples immediately after application of the samples, 37
It shows the detection results after evaporating water by storing at 3 ° C. for 3 days and 6 days. As is clear from Table 1 below, there is no difference in the detection results over time, and human Hb in the sample
It can be seen that the denaturation with time is suppressed.

【0045】[0045]

【表1】 [Table 1]

【0046】実施例2 本実施例は、標識化された第二の抗体を、予め吸水性基
材に固定化しておき、展開液だけを試料に加えた場合の
例である。試料の種類および作製方法は実施例1と同様
である。
Example 2 This example is an example in which the labeled second antibody is immobilized on the water-absorbent substrate in advance and only the developing solution is added to the sample. The type of sample and the manufacturing method are the same as in Example 1.

【0047】(1)吸水性基材に対する、標識化された
第二の抗体の固定化 吸水性基材、第一の抗体の固定は実施例1と同様とし、
さらにニトロセルロース/PETフィルムを形成した。
標識化された第二の抗体は、上記実施例1と同様、青色
ラテックス粒子によって標識化された抗ヒトHbウサギ
ポリクロナール抗体を用いた。この標識化された第二の
抗体(固形分1%)1μlと10%サッカロース水溶液
4μlの混合液を、レーヨン不織布(厚さ0.4mm、
5×3mm)に塗布し、室温でデシケーター内で一夜乾
燥した。この不織布を吸水性基材の吸水部端から20m
mの部位に貼布し、標識化された第二の抗体を吸水性基
材に固定した。
(1) Immobilization of labeled second antibody to water-absorbent substrate Immobilization of the water-absorbent substrate and the first antibody was carried out in the same manner as in Example 1,
Further, a nitrocellulose / PET film was formed.
As the labeled second antibody, an anti-human Hb rabbit polyclonal antibody labeled with blue latex particles was used as in Example 1 above. A mixed solution of 1 μl of the labeled second antibody (solid content 1%) and 4 μl of a 10% sucrose aqueous solution was mixed with a rayon non-woven fabric (thickness 0.4 mm,
5 × 3 mm) and dried overnight in a desiccator at room temperature. This non-woven fabric is 20 m from the edge of the water absorbing part of the water absorbent base material.
It was applied to the site m and the labeled second antibody was immobilized on the water-absorbent substrate.

【0048】(2)試料中のヒトHbの検出 このニトロセルロース/PETフィルムのPET貫通孔
内に、ヒトHbを含有する試料を実施例1と同様にして
塗布し充填した。展開液として0.1Mリン酸緩衝液
(NaCl;0.9%、アジ化ナトリウム;0.1%含
有、pH7.4)100μlを、試料を塗布した直後に
吸水性基材に対して吸水部から添加し、試料を第一の抗
体の領域まで到達させて、10分後の固定部の発色を肉
眼で観察した。また、同じ試料を同様の方法で配置した
吸水性基材を別途作製し、実施例1と同様の条件で、3
7℃で3日間、および6日間保存し水分を蒸発させた
後、前記と同様に分散液を添加して検出を行った。
(2) Detection of Human Hb in Sample A sample containing human Hb was applied and filled in the PET through holes of this nitrocellulose / PET film in the same manner as in Example 1. Immediately after applying the sample, 100 μl of 0.1 M phosphate buffer (NaCl; 0.9%, containing sodium azide; 0.1%, pH 7.4) was used as a developing solution for the water-absorbent substrate immediately after the application. The sample was allowed to reach the area of the first antibody, and the color of the fixed part was observed with the naked eye after 10 minutes. In addition, a water-absorbent substrate in which the same sample is arranged by the same method is separately prepared, and the water-absorbent substrate is prepared under the same conditions as in Example 1 to
After storing at 7 ° C. for 3 days and 6 days to evaporate the water content, the dispersion liquid was added and detection was performed as described above.

【0049】下記表2は、本実施例における検出結果を
示すものであり、上記表1と同様、検出結果に経時的な
差異がなく、試料中のヒトHbの経時的な変性が抑制さ
れていることがわかる。
The following Table 2 shows the detection results in this Example. Similar to Table 1 above, there is no difference in the detection results over time, and the denaturation of human Hb in the sample over time is suppressed. You can see that

【0050】[0050]

【表2】 [Table 2]

【0051】実施例3 本実施例は、試料の糞便を配置するに際し、別途用意し
た試料配置用部材に試料を塗布し、これを吸水性基材に
添付した場合の例である。試料の種類および作製方法は
実施例1と同様である。
Example 3 This example is an example in which the sample is applied to a separately prepared sample placement member when the feces of the sample are placed, and the sample is attached to the water-absorbent substrate. The type of sample and the manufacturing method are the same as in Example 1.

【0052】(1)試料の配置 試料配置用部材として外形φ2mmの濾紙(No.1)
を用いた。 この試料配置用部材を、1%ウシ血清アル
ブミン水溶液に1時間浸漬した後、乾燥させ、試料を厚
さ約25μmで塗布した。
(1) Arrangement of sample As a member for sample arrangement, a filter paper having an outer diameter of 2 mm (No. 1)
Was used. This sample placement member was immersed in a 1% bovine serum albumin aqueous solution for 1 hour, then dried, and the sample was applied to a thickness of about 25 μm.

【0053】(2)試料中のヒトHbの検出 上記試料配置用部材を、第二の抗体および第一の抗体が
実施例2と同様の態様にて固定化されたニトロセルロー
ス/PETフィルム(ただしPETには貫通孔がないも
の)の吸水部端から10mmの部位に貼付し、実施例2
と同様にしてヒトHbの検出を行った。また、同じ試料
を塗布した同様の濾紙を同様の方法で添付した吸水性基
材を別途作製し、実施例1、2と同様の条件で、37℃
で3日間、および6日間保存し水分を蒸発させた後、前
記と同様に分散液を添加して検出を行った。これら本実
施例の検出結果は、上記実施例1、2と全く同様であ
り、検出結果に経時的な差異がなく、試料中のヒトHb
の経時的な変性が抑制されていることがわかった。
(2) Detection of Human Hb in Sample A nitrocellulose / PET film (provided that the second antibody and the first antibody are immobilized in the same manner as in Example 2) on the sample placement member (however, (PET does not have a through hole) is attached to a portion 10 mm from the end of the water absorbing portion, and
Human Hb was detected in the same manner as in. In addition, a water-absorbent substrate was separately prepared by attaching the same filter paper coated with the same sample in the same manner, and the conditions were the same as in Examples 1 and 2, and the temperature was 37 ° C.
After storing for 3 days and 6 days to evaporate the water content, the dispersion liquid was added and detection was performed in the same manner as above. The detection results of these Examples are exactly the same as those of Examples 1 and 2 described above, and there is no difference in the detection results over time.
It was found that the denaturation of the above was suppressed.

【0054】比較例 本比較例は、試料の糞便を配置するに際し、従来の方法
に従い、試料を緩衝液に溶解して保存し、これを吸水性
基材に添付し展開させた場合の例である。試料の種類お
よび作製方法は実施例1と同様である。
Comparative Example This comparative example is an example in which the sample was dissolved and stored in a buffer solution according to a conventional method when the feces of the sample were placed, and the sample was attached to a water-absorbent substrate and developed. is there. The type of sample and the manufacturing method are the same as in Example 1.

【0055】実施例3と比較例とで、検出1回当たりの
糞便の量を同じにするため、実施例3で作製した、試料
を塗布したφ2mmの濾紙10枚を0.1Mリン酸緩衝
液(NaCl;0.9%、アジ化ナトリウム;0.1%
含有、pH7.4)1mlに浸漬し、よく振とうして試
料を完全に溶解した。この溶解液100μlを実施例3
と同様のニトロセルロース/PETフィルム(第二の抗
体、第一の抗体が固定されたもの)に添加し、ヒトHb
の検出を行った。また、同じ溶解液を、37℃で3日
間、および6日間保存した後、前記と同様の検出を行っ
た。
In order to make the amount of feces per one detection the same in Example 3 and Comparative Example, 10 sheets of φ2 mm filter paper coated with the sample prepared in Example 3 were used in 0.1 M phosphate buffer solution. (NaCl; 0.9%, sodium azide; 0.1%
The sample was completely dissolved by immersing in 1 ml of the solution (pH 7.4). 100 μl of this lysate was used in Example 3.
Add to the same nitrocellulose / PET film (the second antibody and the first antibody are fixed), human Hb
Was detected. Further, the same lysate was stored at 37 ° C. for 3 days and 6 days, and then the same detection as described above was performed.

【0056】下記表3は、本比較例における検出結果を
示すものである。同表から明らかなように、試料の保存
3日目以降で検出感度付近の検体が陰性化しており、糞
便溶解液を用いる従来の免疫クロマト法では、試料中の
ヒトHbが経時的に変性し易いことが確認できた。
Table 3 below shows the detection results in this comparative example. As is clear from the table, the samples near the detection sensitivity became negative after the third day of storage of the sample, and in the conventional immunochromatographic method using the fecal lysate, human Hb in the sample was denatured with time. It was confirmed that it was easy.

【0057】[0057]

【表3】 [Table 3]

【0058】[0058]

【発明の効果】本発明により、免疫クロマト法を適用し
て糞便中のヒトHbを検出する操作手順が簡便となる。
特に試料が多数の場合に、その操作手順の簡便化はより
顕著な検査時間の短縮効果として現れる。即ち、試料が
配置された吸水性基材が多数あっても、それらに対し
て、共通の展開液を付与するだけでよいからである。ま
た、検出機器へセットするまでの段取りが短縮されるこ
とによって、自動検出装置のラインに乗せるメリットが
出てくる。また、個々の試料が溶解された容器が多数集
合する状態が1段階無くなったことによって、検体を取
り違える事故の発生確率が格段に減少した。また、検体
が数日間放置された場合でも偽陰性化することが抑制さ
れ、信頼性のある、結果を得ることが出来るようになっ
た。
EFFECTS OF THE INVENTION According to the present invention, the operational procedure for detecting human Hb in feces by applying the immunochromatography method becomes simple.
Particularly when the number of samples is large, simplification of the operation procedure appears as a more remarkable effect of shortening the inspection time. That is, even if there are many water-absorbent substrates on which the sample is arranged, it is only necessary to apply a common developing solution to them. In addition, the setup required for setting to the detection device is shortened, which brings the merit of putting it on the line of the automatic detection device. In addition, the number of containers in which individual samples have been dissolved is eliminated by one stage, and thus the probability of an accident in which samples are mixed up is significantly reduced. Further, even if the sample is left for several days, it is possible to suppress the false negative reaction and obtain reliable results.

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明による検出方法に従って、糞便中のヒト
Hbの検出を行なっている状態を模式的に示す図であ
る。
FIG. 1 is a diagram schematically showing a state of detecting human Hb in feces according to the detection method of the present invention.

【図2】吸水性基材上に第二の抗体を固定する場合の態
様を模式的に示す図である。
FIG. 2 is a diagram schematically showing an embodiment in which a second antibody is immobilized on a water-absorbent substrate.

【符号の説明】[Explanation of symbols]

1 第一の抗体 2 第二の抗体 3 試料 4 吸水性基材 5 展開液 1 first antibody 2 second antibody 3 sample 4 water-absorbent substrate 5 developing solution

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 第一の抗ヒトヘモグロビン抗体が固定化
された領域を有する吸水性基材上の前記領域外に、試料
の糞便を配置した後、免疫クロマト法に従い、試料中の
ヒトヘモグロビンに、標識化された第二の抗ヒトヘモグ
ロビン抗体を結合させ、これを展開液によって前記第一
の抗ヒトヘモグロビン抗体が固定化された領域まで展開
させて、試料中のヒトヘモグロビンと第一の抗ヒトヘモ
グロビン抗体と標識化された第二の抗ヒトヘモグロビン
抗体との複合体を形成させ第一の領域に捕捉することに
よって、試料中のヒトヘモグロビンを検出することを特
徴とする糞便中のヒトヘモグロビンの検出方法。
1. A human anti-hemoglobin in a sample is placed according to immunochromatography after stool of the sample is placed outside the region on the water-absorbing substrate having the region where the first anti-human hemoglobin antibody is immobilized. , A labeled second anti-human hemoglobin antibody is bound, and this is developed to a region where the first anti-human hemoglobin antibody is immobilized by a developing solution, and human hemoglobin in the sample and the first anti-human hemoglobin antibody are immobilized. Human hemoglobin in feces characterized by detecting human hemoglobin in a sample by forming a complex between a human hemoglobin antibody and a labeled second anti-human hemoglobin antibody and capturing the complex in the first region Detection method.
【請求項2】 試料の糞便の配置が、試料の糞便を厚さ
3mm以下に塗布することによってなされるものである
請求項1記載の糞便中のヒトヘモグロビンの検出方法。
2. The method for detecting human hemoglobin in feces according to claim 1, wherein the feces in the sample are arranged by applying the feces in the sample to a thickness of 3 mm or less.
【請求項3】 試料の糞便の塗布が、試料の糞便を試料
塗布部材に塗布した後、これを吸水性基材に接触させ転
写させることによってなされるものである請求項2記載
の糞便中のヒトヘモグロビンの検出方法。
3. The feces of the sample according to claim 2, wherein the application of the feces of the sample is performed by applying the feces of the sample to the sample application member and then bringing the sample into contact with the water-absorbent substrate and transferring the same. A method for detecting human hemoglobin.
【請求項4】 試料中のヒトヘモグロビンと、標識化さ
れた第二の抗ヒトヘモグロビン抗体との結合が、展開液
に標識化された第二の抗ヒトヘモグロビン抗体を含有さ
せることによってなされるものである請求項1〜3記載
の糞便中のヒトヘモグロビンの検出方法。
4. Binding of human hemoglobin in a sample to a labeled second anti-human hemoglobin antibody by incorporating a labeled second anti-human hemoglobin antibody in the developing solution. The method for detecting human hemoglobin in feces according to claims 1 to 3.
【請求項5】 試料中のヒトヘモグロビンと、標識化さ
れた第二の抗ヒトヘモグロビン抗体との結合が、配置さ
れた試料の糞便と、第一の抗ヒトヘモグロビン抗体が固
定化された領域との間に、標識化された第二の抗ヒトヘ
モグロビン抗体が固定化された領域を設けることによっ
てなされるものである請求項1〜3記載の糞便中のヒト
ヘモグロビンの検出方法。
5. The binding between the human hemoglobin in the sample and the labeled second anti-human hemoglobin antibody is caused by the feces of the arranged sample and the region where the first anti-human hemoglobin antibody is immobilized. The method for detecting human hemoglobin in feces according to claims 1 to 3, which is carried out by providing a region in which the labeled second anti-human hemoglobin antibody is immobilized.
【請求項6】 試料中のヒトヘモグロビンと、標識化さ
れた第二の抗ヒトヘモグロビン抗体との結合が、配置さ
れた試料の糞便を挟んで、第一の抗ヒトヘモグロビン抗
体が固定化された領域とは反対側の領域に、標識化され
た第二の抗ヒトヘモグロビン抗体を固定化し、該標識化
された第二の抗ヒトヘモグロビン抗体に展開液を先に加
え、これを配置された試料の糞便へ展開させることによ
ってなされるものである請求項1〜3記載の糞便中のヒ
トヘモグロビンの検出方法。
6. The binding between the human hemoglobin in the sample and the labeled second anti-human hemoglobin antibody is such that the first anti-human hemoglobin antibody is immobilized with the feces of the sample placed therebetween. In a region opposite to the region, a labeled second anti-human hemoglobin antibody is immobilized, a developing solution is first added to the labeled second anti-human hemoglobin antibody, and a sample in which this is arranged The method for detecting human hemoglobin in feces according to claims 1 to 3, wherein the method is carried out by developing into human feces.
JP29870295A 1995-11-16 1995-11-16 Method for detecting human hemoglobin in feces Expired - Fee Related JP3490560B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP29870295A JP3490560B2 (en) 1995-11-16 1995-11-16 Method for detecting human hemoglobin in feces

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29870295A JP3490560B2 (en) 1995-11-16 1995-11-16 Method for detecting human hemoglobin in feces

Publications (2)

Publication Number Publication Date
JPH09145710A true JPH09145710A (en) 1997-06-06
JP3490560B2 JP3490560B2 (en) 2004-01-26

Family

ID=17863186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP29870295A Expired - Fee Related JP3490560B2 (en) 1995-11-16 1995-11-16 Method for detecting human hemoglobin in feces

Country Status (1)

Country Link
JP (1) JP3490560B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10132820A (en) * 1996-10-28 1998-05-22 Okuto:Kk Immunological inspecting appliance
JPH10132816A (en) * 1996-10-28 1998-05-22 Nitto Denko Corp Immunologic inspection implement
WO2000002049A1 (en) * 1998-07-01 2000-01-13 Nitto Denko Corporation Immunologic test method and immunologic test kit
KR20020079488A (en) * 2001-04-06 2002-10-19 마쯔시다덴기산교 가부시키가이샤 Immunochromato device and method for measuring samples using the same
JP2016526893A (en) * 2013-07-17 2016-09-08 ロレアル Biomolecule extractor and biomolecule extraction method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10132820A (en) * 1996-10-28 1998-05-22 Okuto:Kk Immunological inspecting appliance
JPH10132816A (en) * 1996-10-28 1998-05-22 Nitto Denko Corp Immunologic inspection implement
WO2000002049A1 (en) * 1998-07-01 2000-01-13 Nitto Denko Corporation Immunologic test method and immunologic test kit
US6753190B1 (en) 1998-07-01 2004-06-22 Nitto Denko Corporation Immunologic test method and immunologic test kit
KR20020079488A (en) * 2001-04-06 2002-10-19 마쯔시다덴기산교 가부시키가이샤 Immunochromato device and method for measuring samples using the same
JP2016526893A (en) * 2013-07-17 2016-09-08 ロレアル Biomolecule extractor and biomolecule extraction method
US10520404B2 (en) 2013-07-17 2019-12-31 L'oreal Biomolecule extraction device and biomolecule extraction method

Also Published As

Publication number Publication date
JP3490560B2 (en) 2004-01-26

Similar Documents

Publication Publication Date Title
US5166051A (en) Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
JP7330945B2 (en) Assays for improved analyte detection
JP6293797B2 (en) Multi-sided lateral flow assay with diverting region
US20070087451A1 (en) Immuno-gold lateral flow assay
US10591470B2 (en) Immunochromatographic analysis method
JPH08501387A (en) Analytical test equipment with negative and positive controls on board
JPS61247965A (en) Enzyme immunological measurement method
BR112012012342A2 (en) SIDE FLOW DEVICE TO DETECT AN ANALYTIS IN A SAMPLE, UNIVERSAL TEST STRIP, SAMPLE COMPRESSOR, METHOD OF APPLYING A SAMPLE TO A TEST STRIP, METHOD OF ACCENTUATING A SIGN ON A LATEST FLOW AND METHOD DEVICE DEVICE AT LEAST ONE ANALYT IN A SAMPLE
GB2342443A (en) Immunoassay device
TWI554759B (en) An immunochromatographic assay device, an immunochromatographic assay, and an immunochromatographic assay kit
JP6084759B1 (en) Immunological detection method and test strip used therefor
KR20030036915A (en) Biosensor and method for analyzing blood components using it
WO2000002049A1 (en) Immunologic test method and immunologic test kit
JP3237848B2 (en) Test element fabrication method
WO2019124532A1 (en) Immunochromatography device
JP3859027B2 (en) Method for measuring specific substances in nipple discharge
JP3490560B2 (en) Method for detecting human hemoglobin in feces
US8664001B2 (en) Immunochemical filter device and methods for use thereof
CA2570383C (en) Filter device, the method, kit and use thereof
JP2002148266A (en) Detector and its manufacturing method
JP4990692B2 (en) Immunochromatographic assay and kit
JP2001228151A (en) Immunological chromatographic device
JP2000028614A (en) Immunological inspection method and immunological inspection kit thereof
JPH09512333A (en) Assay device
JP3713178B2 (en) Immunoanalyzer for syphilis antibody detection

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees